Moreover, the frequency of MUC4 and MUC16 mutations in our study was considerably higher than that reported in a previous study on MYCN non-amplified neuroblastoma (70% vs. 26% for MUC4 and 38% vs. 14% for MUC16). This evidence concerns the gene MUC4 and neuroblastoma.